Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies

Fluocinolone acetonide (FAc) intravitreal implant (Iluvien(®)) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non–infectious posterior uveitis, and as an off-label treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Mushtaq, Yusuf, Mushtaq, Maryam M, Gatzioufas, Zisis, Ripa, Matteo, Motta, Lorenzo, Panos, Georgios D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069638/
https://www.ncbi.nlm.nih.gov/pubmed/37020801
http://dx.doi.org/10.2147/DDDT.S403259
_version_ 1785018886894125056
author Mushtaq, Yusuf
Mushtaq, Maryam M
Gatzioufas, Zisis
Ripa, Matteo
Motta, Lorenzo
Panos, Georgios D
author_facet Mushtaq, Yusuf
Mushtaq, Maryam M
Gatzioufas, Zisis
Ripa, Matteo
Motta, Lorenzo
Panos, Georgios D
author_sort Mushtaq, Yusuf
collection PubMed
description Fluocinolone acetonide (FAc) intravitreal implant (Iluvien(®)) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non–infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders.
format Online
Article
Text
id pubmed-10069638
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-100696382023-04-04 Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies Mushtaq, Yusuf Mushtaq, Maryam M Gatzioufas, Zisis Ripa, Matteo Motta, Lorenzo Panos, Georgios D Drug Des Devel Ther Review Fluocinolone acetonide (FAc) intravitreal implant (Iluvien(®)) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non–infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders. Dove 2023-03-30 /pmc/articles/PMC10069638/ /pubmed/37020801 http://dx.doi.org/10.2147/DDDT.S403259 Text en © 2023 Mushtaq et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Mushtaq, Yusuf
Mushtaq, Maryam M
Gatzioufas, Zisis
Ripa, Matteo
Motta, Lorenzo
Panos, Georgios D
Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
title Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
title_full Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
title_fullStr Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
title_full_unstemmed Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
title_short Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
title_sort intravitreal fluocinolone acetonide implant (iluvien(®)) for the treatment of retinal conditions. a review of clinical studies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069638/
https://www.ncbi.nlm.nih.gov/pubmed/37020801
http://dx.doi.org/10.2147/DDDT.S403259
work_keys_str_mv AT mushtaqyusuf intravitrealfluocinoloneacetonideimplantiluvienforthetreatmentofretinalconditionsareviewofclinicalstudies
AT mushtaqmaryamm intravitrealfluocinoloneacetonideimplantiluvienforthetreatmentofretinalconditionsareviewofclinicalstudies
AT gatzioufaszisis intravitrealfluocinoloneacetonideimplantiluvienforthetreatmentofretinalconditionsareviewofclinicalstudies
AT ripamatteo intravitrealfluocinoloneacetonideimplantiluvienforthetreatmentofretinalconditionsareviewofclinicalstudies
AT mottalorenzo intravitrealfluocinoloneacetonideimplantiluvienforthetreatmentofretinalconditionsareviewofclinicalstudies
AT panosgeorgiosd intravitrealfluocinoloneacetonideimplantiluvienforthetreatmentofretinalconditionsareviewofclinicalstudies

Ejemplares similares